Comparing the current results to its competitors, Kalvista Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 0 % year on year. The revenue growth was below Kalvista Pharmaceuticals Inc 's competitors' average revenue growth of 18.53 %, achieved in the same quarter.
Kalvista Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 176.92 %
Kalvista Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes firms with substantially greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing. Industry mergers and acquisitions may consolidate resources among fewer competitors. Smaller and early-stage companies can also be significant competitors, particularly through collaborations with larger, established firms. The availability of generic products is anticipated to increase pricing pressure. Competitors may develop products that offer improved safety, efficacy, convenience, or cost advantages. Pharvaris is identified as a competitor and has initiated a Phase 3 trial for deucrictibant XR as a preventative treatment.
November 6, 2025
In an era marked by remarkable pharmaceutical breakthroughs, KalVista Pharmaceuticals, Inc. has recently highlighted the significant patient satisfaction associated with EKTERLY (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE). This novel therapeutic agent was the focus of a presentation at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI), where new data underscored its potential impact on patients aged 2 to 11 years.Hereditary angioedema, a genetic disorder characterised by recurrent episodes of severe swelling, poses considerable physical and emotional challenges for affected individuals and their families. Unti...
September 11, 2025
In a world where pharmaceutical breakthroughs can change the lives of thousands, few stories exemplify the triumphs and tribulations of drug development like that of KalVista Pharmaceuticals, Inc. (Nasdaq: KALV). Recently, the company provided an operational update and financial results for the fiscal quarter ending July 31, 2025, unveiling both a monumental achievement and a significant hurdle in its quest to revolutionize treatment for hereditary angioedema (HAE). A Momentous Achievement: FDA Approval of EKTERLY On a day that will undoubtedly be marked on the company’s timeline, KalVista celebrated the FDA s approval of EKTERLY. This treatment is particularly noteworthy as it represents the first and onl...
February 4, 2025
In a recent announcement, KalVista Pharmaceuticals, based in Cambridge, Massachusetts, and Salisbury, England, disclosed it has granted stock options to incentivize new hires as part of its strategy to attract talented individuals in the competitive biopharmaceutical sector. Under Nasdaq Listing Rule 5635(c)(4), the company s compensation committee has authorized the issuance of inducement options to 52 newly-hired employees.On February 3, 2025, KalVista will provide a total of 261,000 shares of its common stock in the form of stock options. One of the key details of this grant is that the exercise price of these options will be equivalent to the closing price of KalVista s common stock on the day of the gra...
January 21, 2025
KalVista Pharmaceuticals Advances in Hereditary Angioedema Treatment Amidst Competitive Challenges KalVista Pharmaceuticals, Inc. a biomedical firm with roots in Cambridge, Massachusetts, and Salisbury, England, has made significant progress in the treatment landscape of hereditary angioedema (HAE) with its recent announcement that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug Designation to its investigational drug, sebetralstat. The company has also submitted a New Drug Application (NDA) for sebetralstat to the relevant Japanese regulatory authority, signaling an intent to bring this novel oral plasma kallikrein inhibitor to market. If approved, sebetralstat would offer...
December 5, 2024
KalVista Pharmaceuticals: Milestones and Advancements in Hereditary Angioedema Treatment KalVista Pharmaceuticals, Inc. based in Cambridge, Massachusetts and Salisbury, England, has recently delivered comprehensive updates on its operational and financial progress, particularly regarding its promising investigational treatment, sebetralstat (KVD824). The company’s second fiscal quarter results for the period ending October 31, 2024, showcased notable achievements that position KalVista as a key player in the biopharmaceutical landscape, particularly in the management of hereditary angioedema (HAE).A central highlight of the quarterly report was the acceptance of a New Drug Application (NDA) for sebetralsta...
November 5, 2024
KalVista Pharmaceuticals: A Strategic Move in the Market Amidst Financial Challenges CAMBRIDGE, Mass. and SALISBURY, England - KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) is making waves in the biotech landscape with its recent announcement of a $55 million underwritten public offering of common stock, along with a concurrent $5 million private placement. The offering, which involves 5,500,000 shares priced at $10.00 each, aims to bolster the company’s financial standing as it navigates the choppy waters of the pharmaceutical sector.Despite facing significant headwinds, including a staggering cumulative net loss of $142 million for the twelve months ending in Q1 2025 and a troubling negative return on ...
October 4, 2024
In a significant advancement for the treatment of hereditary angioedema (HAE), KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has presented compelling data on its investigational drug, sebetralstat. The results highlight not only the drug s efficacy in alleviating HAE attacks but also its potential to reduce associated anxiety, an important consideration for patients who frequently grapple with this debilitating condition. Key findings were showcased at two pivotal forums the HAEi Global Angioedema Forum (GAF) held in Copenhagen, Denmark, on October 4-5, 2024, and the Bradykinin Symposium in Berlin, Germany, on September 5-6, 2024.The insights shared at GAF were rooted in data from the KONFIDENT phase 3 clini...
September 5, 2024
KalVista Pharmaceuticals, Inc. has recently published its operational update and financial results for the first fiscal quarter ended July 31, 2024. Disclosing strategic advancements in their business, the company highlights the acceptance of its New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) as a significant milestone in their ongoing drug development efforts. Additionally, the validation of their Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) marks another critical achievement in the expansion of their pharmaceutical portfolio.Ben Palleiko, the CEO of KalVista, expressed enthusiasm regarding the company s progress. He stated, We are excited about...
August 15, 2024
In this eminent age of scientific inquiry and burgeoning pharmacology, it becomes exceedingly paramount to document with scholarly precision the latest developments that burgeon forth from the hallowed halls of medical research. It is with unbridled elation that one announces the recent news emanating from KalVista Pharmaceuticals, a renowned entity passionately dedicated to harnessing the intricacies of biopharmaceutical innovation.On this illustrious day, KalVista Pharmaceuticals, located in the historic city of Cambridge, Massachusetts, alongside the picturesque town of Salisbury in England, has proclaimed the validation of its application for marketing authorization by the venerable European Medicines Ag...
June 18, 2024
KalVista Pharmaceuticals, a leading biopharmaceutical company, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sebetralstat. This oral plasma kallikrein inhibitor serves as an on-demand treatment for hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older. The NDA submission represents a significant milestone for the company, aimed at addressing the persisting unmet needs of HAE patients.Facts:1. Advancing Treatment Options: Sebetralstat, an investigational drug developed by KalVista Pharmaceuticals, has been submitted for FDA review as a potential oral on-demand therapy for HAE. If approved, it would be the first ora...
Publicly Traded Peers of Kalvista Pharmaceuticals Inc
Apellis Pharmaceuticals Inc Share Performance
+0.05%
Over The Past 5 Days
Apellis Pharmaceuticals Inc
Profile
Apellis Pharmaceuticals Inc operates under a business model that focuses on the research, development, and commercialization of novel therapies for various medical conditions, with a particular emphasis on complement immunotherapy. They aim to bring innovative drugs to market that can positively impact patients' lives worldwide.
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
Grifols SA operates a business model that focuses on plasma-derived medicine production and commercialization, including plasma collection, testing, and fractionation, as well as the development of diagnostic equipment and transfusion medicine. Their core activities involve the extraction of plasma, transforming it into life-saving therapies, and distributing them worldwide to healthcare providers.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Sources:
Kalvista Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kalvista Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
